Form 8-K BIOGEN INC. For: Apr 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
RBC Capital on Biogen (BIIB): 'CMS Makes It Clear - Leqembi Will Be Broadly Reimbursed - Should Reduce Overhang'
April 26, 2023 3:16 PM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $340.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "We believe many people have been on the sidelines on BIIB because of concerns around Leqembi events this year - upcoming competitor data from LLY, an AdComm, the PDUFA for potential full approval, and CMS decision on reimbursement. Our sense has been that reimbursement is the biggest uncertainty weighing on the stock and on perceptions around Leqembi's long-term potential, as despite CMS's contention they will broaden reimbursement as soon as the drug... More
Biogen (BIIB) Tops Q1 EPS by 12c, Offers Guidance
April 25, 2023 7:04 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $3.40, $0.12 better than the analyst estimate of $3.28. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.34 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.48.
Total... More